Bioventus (BVS) Q1 2026 earnings summary

Executive summary

• Q1 2026 revenue rose 7% year-over-year to $132.1 million, exceeding expectations with growth across all business segments and strong commercial execution.

• Net income turned positive at $3.1 million–$4 million, reversing a prior-year loss, and Adjusted EBITDA increased 24% to $23.9–$24 million.

• Raised full-year guidance for adjusted EPS and cash from operations, reflecting confidence in continued momentum.

• Accelerated investments in four key growth drivers, with PNS receiving the largest share and a new general manager appointed.

• Focused on strengthening commercial, operational, and financial fundamentals to support long-term growth.

Financial highlights

• Net sales reached $132.1 million, up 7% year-over-year, with all segments contributing.

• Adjusted EBITDA rose 24% to $23.9–$24 million, with margin expanding to 18%.

• Adjusted EPS was $0.15, nearly double the prior year’s $0.08; GAAP EPS was $0.04, up from a loss of $0.04.

• Gross margin improved to 68.7% GAAP and 76.4% non-GAAP, aided by favorable rebates and tariff refunds.

• Cash from operations totaled $8.9–$9 million, a $28 million improvement year-over-year, with $36 million in cash and $272 million in debt after a $22 million reduction.

Outlook and guidance

• Raised adjusted EPS guidance to $0.75–$0.79 and cash from operations to $84–$89 million, both up from prior guidance.

• Reaffirmed full-year revenue guidance of $600–$610 million.

• Expects acceleration in revenue, adjusted EBITDA, and EPS growth in the second half of 2026 as investments ramp up.

• Projected net leverage ratio to fall below 2 by end of Q2 2026, ahead of schedule.

• Management expects sufficient liquidity for the next twelve months, supported by cash, revolver availability, and operating cash flows.